CGEM Stock Summary and Trading Ideas (Cullinan Therapeutics | NASDAQ:CGEM)

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Cullinan Therapeutics trades on the NASDAQ stock market under the symbol CGEM.

As of January 22, 2026, CGEM stock price climbed to $12.57 with 1,289,926 million shares trading.

CGEM has a beta of 0.67, meaning it tends to be less sensitive to market movements. CGEM has a correlation of 0.03 to the broad based SPY ETF.

CGEM has a market cap of $742.57 million. This is considered a Small Cap stock.

In the last 3 years, CGEM traded as high as $30.19 and as low as $5.68.

The top ETF exchange traded funds that CGEM belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

CGEM has outperformed the market in the last year with a price return of +20.6% while the SPY ETF gained +15.5%. CGEM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +48.2% and +14.9%, respectively, while the SPY returned +2.9% and -0.1%, respectively.

CGEM support price is $11.13 and resistance is $12.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEM shares will trade within this expected range on the day.